In a 17‑year‑old female with inattentive ADHD who has failed methylphenidate, experienced appetite suppression with amphetamine/dextroamphetamine, and has avoidant personality disorder and possible autism, is bupropion (Wellbutrin) an appropriate medication choice?

Bupropion (Wellbutrin) for ADHD in This Clinical Context

Bupropion is a reasonable second-line option for this 17-year-old with inattentive ADHD who has failed methylphenidate and experienced appetite suppression with amphetamines, though it is not FDA-approved for ADHD and has weaker evidence than first-line treatments.

Evidence-Based Rationale

FDA Approval Status and Guidelines

Bupropion is not FDA-approved for ADHD treatment 1. The 2019 AAP guidelines clearly state that stimulants (methylphenidate and amphetamines) are first-line with an effect size of 1.0, while FDA-approved nonstimulants (atomoxetine, extended-release guanfacine, extended-release clonidine) have effect sizes around 0.7 2. The guidelines emphasize that "it is less likely that PCCs need to consider the off-label use of other medications" given the expanded list of FDA-approved options 2.

Why Bupropion May Work Here

Despite lack of FDA approval, bupropion has demonstrated efficacy comparable to methylphenidate in multiple randomized controlled trials:

• Direct comparison studies show bupropion produces equivalent improvement to methylphenidate on ADHD rating scales in children and adolescents 3, 4
• A 2014 systematic review found no significant difference in efficacy between bupropion and methylphenidate for ADHD symptoms 5
• Bupropion has a more favorable side-effect profile than tricyclic antidepressants and may be better tolerated than stimulants in some patients 6

Critical Considerations for This Patient

Advantages in this case:

• No appetite suppression: Unlike the amphetamine/dextroamphetamine that caused problems, bupropion typically does not suppress appetite 1
• May help with comorbid depression: If avoidant personality disorder includes depressive features, bupropion is FDA-approved for major depressive disorder 1
• Reasonable tolerability: Comparable discontinuation rates to methylphenidate in trials 5

Important warnings from FDA label:

• Seizure risk increases with dose - particularly concerning if there's any history of eating disorder (which you should specifically rule out given the appetite issues with prior medication) 1
• Psychiatric symptoms: Can cause unusual thoughts, behaviors, hallucinations, or paranoia - relevant given the avoidant personality disorder and possible autism 1
• Manic episodes: Monitor for increased energy, racing thoughts, reckless behavior 1

Better First-Line Alternatives to Consider

Before choosing bupropion, you should trial the FDA-approved nonstimulants that have stronger evidence:

1. Atomoxetine (first choice): Effect size 0.7, FDA-approved, particularly effective for inattention 2. In autism with ADHD, atomoxetine reduces inattention (SMD = -0.54) and hyperactivity with a benign side-effect profile 7, 8

2. Extended-release guanfacine or clonidine: FDA-approved with effect size 0.7, may help with anxiety symptoms common in avoidant personality disorder 2

Autism-Specific Evidence

The 2021 meta-analysis on ADHD treatment in autism found:

• Methylphenidate and atomoxetine have direct evidence for efficacy in reducing ADHD symptoms in youth with ASD 7
• Bupropion evidence is preliminary or nonexistent in the autism population 8
• Given the possible autism diagnosis, this strengthens the case for atomoxetine over bupropion

Clinical Algorithm

Step 1: Since methylphenidate failed and amphetamine caused appetite suppression, move to FDA-approved nonstimulants:

• Try atomoxetine first (dose: start 0.5 mg/kg/day, target 1.2 mg/kg/day)

Step 2: If atomoxetine fails or is not tolerated:

• Consider extended-release guanfacine (1-4 mg/day) or clonidine

Step 3: If all FDA-approved options have been exhausted:

• Then consider bupropion (150 mg daily for 1 week, then 300 mg daily if tolerated) 1

Critical Screening Before Bupropion

If you proceed with bupropion, mandatory screening:

• Rule out eating disorder history (anorexia, bulimia) - absolute contraindication 1
• Rule out seizure history - absolute contraindication 1
• Assess for bipolar disorder - risk of manic episodes 1
• Check blood pressure - can cause hypertension 1
• Screen for suicidal ideation - black box warning for antidepressants in adolescents 1

Communication Challenges

Given this patient "does not talk much," the avoidant personality disorder and possible autism create monitoring challenges. You need:

• Structured rating scales (not just verbal report) to assess response
• Collateral information from parents/teachers using standardized ADHD rating scales 2
• Specific adverse event monitoring using checklists rather than open-ended questions

Bottom Line

Bupropion is a defensible third-line choice after FDA-approved nonstimulants have been tried, but atomoxetine should be the next medication attempted given stronger evidence, FDA approval, and specific data in autism populations 2, 7, 8. The lack of appetite suppression makes bupropion appealing, but this advantage is shared by atomoxetine and the alpha-2 agonists.